- Home
- OTLK vs GMM Comparison
OTLK vs GMM Comparison
Compare OTLK & GMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | GMM |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 39.6M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | OTLK | GMM |
|---|---|---|
| Price | $0.51 | $1.25 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $3.83 | N/A |
| AVG Volume (30 Days) | ★ 12.7M | 43.9K |
| Earning Date | 02-13-2026 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,413,535.00 | ★ $55,941,283.00 |
| Revenue This Year | $1,578.49 | N/A |
| Revenue Next Year | $153.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.50 | $0.94 |
| 52 Week High | $3.39 | $4.75 |
Technical Indicators
Market Signals| Indicator | OTLK | GMM |
|---|---|---|
| Relative Strength Index (RSI) | 25.51 | 39.19 |
| Support Level | $0.51 | $1.28 |
| Resistance Level | $0.54 | $1.45 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 16.19 | 2.22 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.